menu search

Center for medicare director has answers to big enrollment questions — join live

Center for Medicare director has answers to big enrollment questions — join live Read Full Story The ...

November 4, 2023, 5:14 pm

Strategic education (stra) q3 earnings beat, enrollment rises

Strategic Education's (STRA) third-quarter 2023 results gain from strong growth across the segments and improved ...

November 3, 2023, 12:47 pm

Morphic announces corporate highlights and financial results for the third quarter 2023

-Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week 2023- -Continued ...

November 3, 2023, 11:00 am

Sofi shares gain as fintech company reports record memberships, boosts guidance

Shares of SoFi Technologies (SOFI) gained ground Monday after the fintech company raised its full-year guidance following a quarter in which it achiev...

October 30, 2023, 5:50 pm

Why stride stock jumped 19.4% this week

Stride announced better-than-expected revenue and a surprise net profit to start its new fiscal year. Growth was punctuated by strong ...

October 26, 2023, 6:18 pm

Scholar rock: sma data readout in 2024 makes this worth a look

The Scholar Rock Holding Corporation phase 3 SAPPHIRE study for apitegromab for the treatment of type 2 and type 2 SMA patients has completed ...

October 25, 2023, 5:44 pm

Robert powell’s retirement portfolio: confused about medicare enrollment? how to get help.

More than 60 million Medicare beneficiaries are in the thick of the annual election period. It can be overwhelming. Read Full Story The post Robert Po...

October 21, 2023, 7:47 pm

Ocean biomedical (nasdaq: ocea) announces enrollment of patients for phase 1b study for chronic hepatitis b treatment in 50-50 joint venture with virion therapeutics

Providence, Rhode Island, Oct. 17, 2023 (GLOBE NEWSWIRE) — Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the deve...

October 17, 2023, 12:01 pm

Clearside biomedical positive oasis and extension study data presented at the retina society 56th annual scientific meeting

– Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – – ODYSSEY Phase 2b Clinical Trial <...

October 16, 2023, 11:05 am

Inhibikase therapeutics highlights unblinded functional analysis from the 201 trial of risvodetinib in untreated parkinson’s disease and provides update on ongoing enrollment

BOSTON and ATLANTA, Oct. 16, 2023 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceu...

October 16, 2023, 11:00 am

Relmada and rel-1017: intriguing underlying efficacy in mdd ahead of eventful 2024

Phase 3 trial failures were due to abnormally high placebo responses driven by poor trial design, enrollment...

October 13, 2023, 7:50 pm

Kronos bio presents positive preliminary data from phase 1 dose escalation portion of phase 1/2 kb-0742 study at aacr-nci-eortc

Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors Showed manage...

October 13, 2023, 4:30 pm

Biocardia (bcda) up on plans for second heart failure study

BioCardia (BCDA) completes enrollment in a pivotal phase III study on its CardiAMP cell therapy for the...

October 12, 2023, 12:47 pm

American public (apei) to gain from affordable online programs

American Public (APEI) is poised to benefit from affordable tuition, strategic initiatives and improved enroll...

October 11, 2023, 1:32 pm

Annexon announces clinical and regulatory progress for anx005 pivotal program in guillain-barré syndrome (gbs)

ANX005 Granted Orphan Drug Designation by the European Medicines Agency for the Treatment of GBS Target enroll...

October 10, 2023, 10:30 am

Why shares of cassava sciences soared this week

A rash of insider buying helped buoy the clinical-stage biotech's stock. Cassava said it had completed the enr...

October 6, 2023, 3:13 pm

Sagimet biosciences announces completion of enrollment of 120 patients for phase 3 clinical trial by its partner ascletis of denifanstat combined with bevacizumab for treatment of recurrent glioblasto

SAN MATEO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing ...

September 27, 2023, 8:05 pm

Sagimet biosciences announces completion of enrollment of 120 patients for phase 3 clinical trial by its partner ascletis of denifanstat combined with bevacizumab for treatment of recurrent glioblasto

SAN MATEO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing ...

September 27, 2023, 8:05 pm

Moleculin (mbrx) posts update from lung cancer study, stock up

Moleculin (MBRX) completes enrollment in the phase II portion of the development program for its lead c...

September 22, 2023, 9:01 am

Why you must add strategic education (stra) stock to portfolio

Strategic Education's (STRA) growth is attributable to solid enrollment, thanks to the strong demand en...

September 18, 2023, 3:03 pm


Search within

Pages Search Results: